To verify whether altered glial glutamate uptake contributes to the reduced efficacy of glutamatergic transmission reported in the prefrontal cortex of schizophrenics, we studied the expression of GLT-1, the transporter responsible for most glutamate transport, in autoptic samples of prefrontal cortex using real time quantitative RT-PCR, immunocytochemistry, and functional assays. GLT-1 mRNA levels in medication-free patients were 2.5-fold higher than in controls, whereas they were normal or reduced in patients treated with antipsychotics. We also observed a 4-fold increase in L-[ 3 H]-Glu uptake in Xenopus oocytes injected with mRNA from the prefrontal cortex of a medication-free schizophrenic and a 2-fold increase in GLT-1 protein in the same cortical area of another medication-free patient. Results suggest that GLT-1 mRNA, protein and function are increased in prefrontal cortex of schizophrenics. Following the demonstration that the psychotomimetic drug phencyclidine blocks NMDA subtypes of glutamate (Glu) receptors, several studies have provided evidence that in schizophrenics an altered function of NMDA receptors may reduce glutamatergic transmission in cortical circuits pivoting in the prefrontal cortex (Tsai and Coyle, 2002).Reduced neocortical glutamatergic signaling can also result from other mechanisms. Glu transporters are important regulators of excitatory transmission and are essential for maintaining physiological Glu levels (Conti and Weinberg, 1999;Danbolt, 2001); increased Glu uptake may thus reduce the efficacy of glutamatergic transmission. The possibility that increased Glu uptake plays a role in the pathophysiology of schizophrenia is suggested by the demonstration that in rat frontal cortex the antipsychotic clozapine reduces the expression and function of GLT-1-the plasma membrane transporter responsible for most Glu transport (Rothstein et al., 1996;Tanaka et al:, 1997)-in a strong and selective manner, thereby raising extracellular Glu levels (Melone et al., 2001(Melone et al., , 2003.We studied 25 samples from the prefrontal cortex (PFC) of 11 schizophrenics and 14 subjects without neurological or psychiatric diseases (hereinafter referred to as controls); 3 of the 11 schizophrenics had not received antipsychotic drugs for an amount of time sufficient to rule out their influence (Baldessarini and